?Shock and Kill? has been described as a method to draw out HIV from latently infected cells with latencyreversing drugs and then utilizing the host immune response to eliminate the infected cells. During the last 5-10 years, a wealth of knowledge has been obtained regarding methods of reactivating latent viruses in various systems (i.e., the ?shock? element). Much less has been learned, however, about the ?kill? element of the strategy. This is, in part, because of the very recent realization that viruses reactivating from latency do not necessarily induce cell death, and infected cells are not automatically rendered susceptible to immune killing. NK cells are part of the innate immune system because their effector function is elicited immediately upon recognition of activation ligands on infected cells without prior exposure to the infected cell or viral antigens. In humans, a decreased ability of NK cells to function correlates with increased severity of HSV (6), CMV (12) and hepatitis B virus (3) infections. Using Dr. Barker?s experience with NK cells, and Drs. Planelles?, Margolis? and Karn?s experience with HIV latency, we will begin to explore the events are required, during reactivation from latency, to render cells efficient targets for autologous NK cells. We also propose to understand how autologous NK cells can most effectively be activated so that killing of infected cells is rapid and complete, following reactivation of latent viruses. These experiments were inspired by our recent finding that a TLR1/2 agonist known as Pam3CSK4 can efficiently reactivate HIV-1 from latency in our model of central memory T cells (Planelles et al., manuscript under review), and by observations by others that TLR stimulation can potentiate the activity of natural killer cells. We have also recently shown that latently infected primary memory T-cells are susceptible to NK-killing after proviral reactivation by SAHA (Checkley and Karn;unpublished). After the above pilot experiments have been optimized and results obtained, it is our next objective to perform similar experiments using aviremic patient cells, being exposed to autologous NK cells, in order to assess relevance and feasibility in a relevant ex vivo system.

Public Health Relevance

It has now become clear that reactivation of latent viruses does not always lead to death of the infected cell. Eradicating latent reservoirs of HIV will, therefore, require active clearance of infected cells. Natural killer cells are of great promise because they do not require priming, and can recognize a variety of virus infected cells in a manner that is independent of the viral antigens. We plan to potentiate the activity of NK cells such that they will recognize and kill latently infected cells when they reactivate.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096113-03
Application #
8725368
Study Section
Special Emphasis Panel (ZAI1-JBS-A (M1))
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$29
Indirect Cost
$9,821
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Dubé, Karine; Dee, Lynda; Evans, David et al. (2018) Perceptions of Equipoise, Risk-Benefit Ratios, and ""Otherwise Healthy Volunteers"" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 13:3-17
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Honeycutt, Jenna B; Liao, Baolin; Nixon, Christopher C et al. (2018) T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest 128:2862-2876
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133

Showing the most recent 10 out of 221 publications